



ICON Medical Imaging Enhances Technology Platform to Expedite Oncology Clinical Trials

Electronic case report form system incorporates RECIST 1.1

DUBLIN, Jun 03, 2010 (BUSINESS WIRE) -- ICON Medical Imaging, a division of ICON Plc (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the enhancement of its ICOSpeedRead(TM) system to incorporate RECIST 1.1 evaluation criteria.

ICOSpeedRead(TM) is a 21 C.F.R. Part 11 compliant electronic case report form system that seamlessly integrates ICON's Medical Imaging database (MIRA) to support the review of medical images in oncology clinical trials. ICOSpeedRead applies the FDA accepted RECIST (Response Evaluation Criteria In Solid Tumors) 1.0 or 1.1 criteria for studies with imaging endpoints including Progression Free Survival, Time to Progression, and Tumor Response.

Sponsors using ICOSpeedRead(TM) for oncology studies are able to begin central image review sessions within 2 weeks compared to the 2-3 month industry standard development time to build and validate electronic case report form systems for blinded imaging reads. Ultimately, this reduced study start-up time provides sponsors with an earlier look at their compound's performance.

Commenting on the innovation, President of ICON Medical Imaging, Ted Gastineau, said: "ICOSpeedRead(TM) is already delivering significant benefits to our clients sponsoring oncology studies. The system is being utilised in ten oncology trials using RECIST 1.1, and we expect this number to triple over the next few months." Gastineau added: "Within the imaging market, we believe our technology innovation is unrivalled. It is currently helping our sponsors to achieve significant time savings and conduct earlier performance evaluations."

ICON Medical Imaging will be demonstrating the ICOSpeedRead(TM) system at the upcoming ASCO meeting being held on June 4th -8th, in Chicago, IL, (Booth #20091).

Notes to Editors:

About ICON

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON teams have successfully conducted over 1,900 development projects and over 2,300 consultancy engagements across all major therapeutic areas. ICON currently has approximately 6,000 employees, operating from 71 locations in 39 countries.

About ICON Medical Imaging

A division of ICON plc, ICON Medical Imaging is the leading provider of Medical Imaging core lab services to pharmaceutical, biotech and life science clients globally. Their extensive experience and expert guidance allow clients to maximize the success of their medical imaging endpoints, supporting their current research and development capabilities. The team at ICON Medical Imaging has managed over 350 trials in oncology, cardiovascular, CNS, medical devices and imaging agents. Further information is available at www.iconplc.com.

ICON/ICLR-G

SOURCE: ICON

ICON

Emily Brand
Corporate Communications Manager
+353-1-2912665

Emily.brand@iconplc.com

Copyright Business Wire 2010